EBM Focus articles provide concise summaries of clinical trials most likely to inform clinical practice curated by the DynaMed® editorial team.

Studies examining the risks of low LDL-C levels have found mixed results, with some demonstrating an association between low levels of LDL-C and an increased risk of intracerebral hemorrhage. Additionally, statin therapy for secondary prevention may increase the risk of intracerebral hemorrhage.

As part of the Kailuan study to investigate risk factors for chronic disease in China, this prospective cohort study followed over 96,000 Chinese adults for nine years, excluding those with myocardial infarction, stroke, or cancer. Fasting lipid profiles, blood pressure, and other health endpoints were collected at baseline and biennially thereafter. Most participants were men (80%) with a normal or overweight body mass index. Participants with LDL >100 mg/dL were more likely to smoke and use anti-hypertensives, aspirin, and cholesterol-lowering agents. During follow-up, 753 cases of intracerebral hemorrhage were identified (0.78%) through survey data, medical records, and death certificates. Average LDL-C levels between 70-90 mg/dL and levels of 100 mg/dL or greater had a similar risk of intracerebral hemorrhage, while lower levels were associated with an increased risk of hemorrhage, even after adjusting for smoking, statin use, hypertension, antiplatelet and anticoagulant use (LDL <50 mg/dL, multivariate-adjusted hazard ratio [aHR] 2.69 [95% CI 2.03-3.57] and LDL 50-69 mg/dL, aHR 1.65 [95%CI 1.32-2.05]). In sensitivity analyses, a similar risk was demonstrated when excluding participants using anticoagulants and statins at follow-up and those with hypertension. Lower total cholesterol concentrations were also associated with a higher risk of intracerebral hemorrhage (TC <120 mg/dL, aHR 2.24 [95% CI 1.48-3.4]), whereas high density lipoprotein cholesterol and triglycerides were not associated with intracerebral hemorrhage.

Clinicians have to navigate the J-shaped curve of relative harms and benefits in many clinical scenarios. Elevated LDL-C >190 mg/d has been consistently associated with cardiovascular death. It appears an LDL-C value below 70 mg/dL may also increase the risk of intracerebral hemorrhage. Some studies have demonstrated an associated increased risk of statin therapy with hemorrhagic stroke, yet the same association has not been demonstrated with proprotein convertase subtilisin/kexin type nine inhibitor therapy. The LDL-C value at which the number needed to treat to prevent cardiovascular events outweighs the number needed to harm to prevent adverse events such as intracerebral hemorrhage has not been identified. While the current guidelines recommend aggressive LDL-C lowering with multiple agents, this is yet another study questioning the safety of driving down LDL-C as low as possible. With regard to statin therapy for patients, the event rate for cardiovascular disease is considerably higher (2% in the same population over four years) than for intracerebral hemorrhage (< 1% over nine years). Finding the perfect LDL-C goal at the base of the J-shaped curve may be difficult and likely varies across different cohorts. Thus, it offers yet another important opportunity for shared decision-making.

For more information, see the topic Intracerebral Hemorrhage in DynaMed.

Earn CME/CE credit for reading this EBM Focus article.